This segment focuses on the research, development, and commercialization of targeted fusion protein therapeutics (TFPTs) for the treatment of various cancers. The primary focus is on Vicineum, a locally-administered TFPT currently in Phase III clinical trials for bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer. Research and development activities include ongoing clinical trials, formulation development, and manufacturing process optimization. The technology platform utilizes TFPTs designed to specifically target cancer cells, minimizing harm to healthy tissues. The patient impact is significant, as Vicineum aims to provide a new treatment option for patients who have failed BCG therapy. Market positioning is centered on addressing unmet needs in bladder cancer treatment, with competitive advantages including a targeted mechanism of action and potential for improved efficacy and safety. Future opportunities include expanding the use of Vicineum to treat other cancers and exploring new TFPTs. Regulatory and clinical aspects involve ongoing interactions with regulatory agencies and the execution of clinical trials. Partnerships and collaborations are essential for manufacturing, commercialization, and clinical trial execution.

This segment encompasses all research and development activities related to the discovery, design, and clinical testing of targeted fusion protein therapeutics. This includes preclinical studies, clinical trial management, and the development of new product candidates. The core technology involves the engineering and development of TFPTs, which are designed to specifically target and destroy cancer cells. Research activities include identifying new cancer targets, designing novel TFPTs, and conducting in vitro and in vivo studies to evaluate their efficacy and safety. Clinical trials are conducted to assess the safety and efficacy of product candidates in human patients. The patient impact is focused on providing innovative treatment options for cancer patients with high unmet medical needs. Market positioning is based on developing innovative cancer therapies with the potential to improve patient outcomes. Future opportunities include expanding the pipeline of product candidates and exploring new therapeutic areas. Regulatory aspects involve interactions with regulatory agencies to obtain approval for clinical trials and product marketing. Partnerships and collaborations are essential for conducting clinical trials and accessing specialized expertise.